Recommendations for COPD management in Central and Eastern Europe

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 report). Available at: https://goldcopd.org/wp-content/uploads/2021/11/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf (Last accessed 2021 Dec 03).
   Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693–718.
   PubMed Web of Science ®Google Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–743.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
   PubMed Web of Science ®Google Scholar
• Ho T, Cusack RP, Chaudhary N, et al. Under-and over-diagnosis of COPD: a global perspective. Breathe. 2019;15(1):24–35.
   Web of Science ®Google Scholar
• Mathioudakis AG, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75(6):520–527.
   PubMed Web of Science ®Google Scholar
• Zbozinkova Z, Barczyk A, Tkacova R, et al. POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. Int J Chron Obstruct Pulmon Dis. 2016;11:611–622.
   PubMed Web of Science ®Google Scholar
• Tabyshova A, Hurst JR, Soriano JB, et al. Gaps in COPD guidelines of low- and middle-income countries: a systematic scoping review. Chest. 2021;159(2):575–584.
   PubMed Web of Science ®Google Scholar
• Aisanov Z, Avdeev S, Arkhipov V, et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:183–187.
   PubMed Web of Science ®Google Scholar
• Vukoja M, Kopitovic I, Lazic Z, et al. Diagnosis and management of chronic obstructive pulmonary disease in Serbia: an expert group position statement. Int J Chron Obstruct Pulmon Dis. 2019;14:1993–2002.
   PubMed Web of Science ®Google Scholar
• Zatloukal J, Brat K, Neumannova K, et al. Chronic obstructive pulmonary disease-diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020;164(4):325–356.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Buhl R, Burghuber O, et al. Guideline for the diagnosis and treatment of COPD patients-issued by the German Respiratory Society and the German Atemwegsliga in cooperation with the Austrian Society of Pneumology. Pneumologie. 2018;72(4):253–308.
   PubMed Web of Science ®Google Scholar
• Sliwinski P, Gorecka D, Jassem E, et al. [Polish Respiratory Society guidelines for chronic obstructive pulmonary disease]. Pneumonologia I Alergologia Polska. 2014;82(3):227–263.
   PubMedGoogle Scholar
• Miravitlles M, Soler-Cataluna JJ. GOLD in 2017: a view from the Spanish COPD guidelines (GesCOPD). Arch Bronconeumol. 2017;53(3):89–90.
   PubMed Web of Science ®Google Scholar
• Gunen H, Kilinc O, Polatli M, et al. Modification of the GOLD recommendations for chronic obstructive pulmonary disease to broaden their usage in Turkey. Expert Rev Respir Med. 2016;10(6):625–628.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637.
   PubMed Web of Science ®Google Scholar
• Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease study 2015. Lancet. 2017;389(10082):1885–1906.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World health statistics data visualizations dashboard. SDG Target 3.a | tobacco control. Tobacco smoking. 2018. Available at: https://apps.who.int/gho/data/node.sdg.3-a-viz?lang=en (Last accessed 2021 Apr 1).
   Google Scholar
• Van Overveld F, Demkow U, Gorecka D, et al. Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. J Physiol Pharmacol. 2006;57:273–282.
   PubMed Web of Science ®Google Scholar
• European Environment Agency. Air quality in Europe - 2019 report. 2019. Available at: https://www.eea.europa.eu/publications/air-quality-in-europe-2019 (Last accessed 2021 Apr 1).
   Google Scholar
• European Environment Agency. Air pollution. 2017. Available at: https://www.eea.europa.eu/themes/air/intro (Last accessed 2021 Apr 1).
   Google Scholar
• Milutinovic S, Nikic D, Stosic L, et al. Short-term association between air pollution and emergency room admissions for chronic obstructive pulmonary disease in Nis, Serbia. Cent Eur J Public Health. 2009;17(1):8.
   PubMedGoogle Scholar
• Kayyali R, Odeh B, Frerichs I, et al. COPD care delivery pathways in five European Union countries: mapping and health care professionals’ perceptions. Int J Chron Obstruct Pulmon Dis. 2016;11:2831–2838.
   PubMed Web of Science ®Google Scholar
• Kamusheva M, Dimitrova M, van Boven JF, et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. J Med Econ. 2017;20(5):503–509.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Escarrabill J, Marrades RM, et al. Differences in COPD care among doctors who control the disease: general practitioner vs. pneumologist. Respir.Med. 2006;100(2):332–339.
   PubMed Web of Science ®Google Scholar
• Pavlov P, Ivanov Y, Glogovska P, et al. New epidemiologic data on COPD in the region of Pleven. Thorac Medic J. 2012;4(2):44–50.
   Google Scholar
• Koblizek V, Jarkovsky J, Dusek L, et al. The Czechia COPD mortality rate declining,but total deaths increasing. Eur Respir J. 2020;56(suppl 64):434.
   Google Scholar
• Korányi National Institute of TB and Pulmonology. Korányi Bulletin. 2019. Available at: https://szakmai.koranyi.hu/bulletin/ (Last accessed 2020 May 28).
   Google Scholar
• Główny Urząd Statystyczny. [Official Journals of the Central Statistical Office]. 2021. Available at: https://dziennikigus.stat.gov.pl/dzienniki-urzedowe-gus/ (Last accessed 2021 Apr 1).
   Google Scholar
• Ulmeanu R, unpublished data. Study of COPD national prevalence in Romania 2019 - project of Romanian Society of Pneumology. Bucharest: MEDICALA.
   Google Scholar
• Cristea C, Matei E, Galan A, et al. Raport Național privind Starea de Sănătate a Populației României 2020. Available at: https://insp.gov.ro/download/cnepss/stare-de-sanatate/rapoarte_si_studii_despre_starea_de_sanatate/starea_de_sanatate/starea_de_sanatate/RAPORTUL-NATIONAL-AL-STARII-DE-SANATATE-A-POPULATIEI-%25E2%2580%2593-2020.pdf (Last accessed 2022 Jan 6).
   Google Scholar
• Republic of Serbia Ministry of Health, Institute of Public Health of Serbia. Results of the National Health Survey of the Republic of Serbia 2013. 2014. Available at: http://www.batut.org.rs/download/publikacije/2013SerbiaHealthSurvey.pdf (Last accessed 2021 Apr 1).
   Google Scholar
• Institute of Public Health of Serbia. Health statistical yearbook of Republic of Serbia 2017. 2018. Available at: http://www.batut.org.rs/download/publikacije/pub2017v026.pdf (Last accessed 2021 Apr 1).
   Google Scholar
• The World Bank. Data: total population. Available at: https://data.worldbank.org/indicator/SP.POP.TOTL (Last accessed 2021 Apr 1).
   Google Scholar
• Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur Respir J. 2017;49(5):ii: 1601446.
   Web of Science ®Google Scholar
• Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38(1):29–35.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Koblizek V, Esquinas C, et al. Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: the POPE study. Respir Med. 2019;150:141–148.
   PubMed Web of Science ®Google Scholar
• Bloom CI, Elkin SL, Quint JK. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–287.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.
   PubMed Web of Science ®Google Scholar
• Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73–83.
   PubMed Web of Science ®Google Scholar
• Alonso JLI, Glez-Moro JMR. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. Arch Bronconeumol. 2012;48(6):207–212.
   PubMed Web of Science ®Google Scholar
• Valipour A, Tamm M, Kocianova J, et al. Improvement in self-reported physical functioning with tiotropium/olodaterol in Central and Eastern European COPD patients. Int J Chron Obstruct Pulmon Dis. 2019;14:2343–2354.
   PubMed Web of Science ®Google Scholar
• Ilić M, Kopitović I, Vulin A, et al. Frequency and effects of seasonal flu vaccines on exacerbations of chronic obstructive pulmonary disease in Serbia. Vojnosanit Pregl. 2019;78(2):179–185.
   Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69.
   PubMed Web of Science ®Google Scholar
• Frei A, Siebeling L, Wolters C, et al. The inaccuracy of patient recall for COPD exacerbation rate estimation and its implications: results from central adjudication. Chest. 2016;150(4):860–868.
   PubMed Web of Science ®Google Scholar
• Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10):1024–1039.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Ferdinande P, Flaatten H, et al. The variability of critical care bed numbers in Europe. Intensive Care Med. 2012;38(10):1647–1653.
   PubMed Web of Science ®Google Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626.
   PubMed Web of Science ®Google Scholar
• Ulmeanu R, Fildan AP, Rajnoveanu RM, et al. Romanian clinical guideline for diagnosis and treatment of COPD. J Int Med Res. 2020;48(8):300060520946907. doi:https://doi.org/10.1177/0300060520946907.
   Google Scholar
• Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–378.
   PubMed Web of Science ®Google Scholar
• Mittal R, Chhabra SK. GOLD classification of COPD: discordance in criteria for symptoms and exacerbation risk assessment. COPD. 2017;14(1):1–6.
   PubMedGoogle Scholar
• Buhl R, de La Hoz A, Xue W, et al. Efficacy of tiotropium/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are naive to LAMA, LABA and ICS: pooled analysis of four clinical trials. Adv Ther. 2020;37(10):4175–4189.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103.
   PubMed Web of Science ®Google Scholar
• Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
   PubMed Web of Science ®Google Scholar
• Buhl R, Criee CP, Kardos P, et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis. 2018;13:2557–2568.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Worth H, Buhl R, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494.
   PubMed Web of Science ®Google Scholar
• O’Byrne P, Fabbri LM, Pavord ID, et al. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54(1):1900491.
   PubMed Web of Science ®Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Price D. Matching inhaler devices with patients: the role of the primary care physician. Can Respir J. 2018;2018:9473051.
   PubMed Web of Science ®Google Scholar
• Hoy H, O’Keefe L. Choosing the right inhaler for the right patient: considerations for effective management of patients with chronic obstructive pulmonary disease or asthma. J Am Assoc Nurse Pract. 2020;32(1):89–99.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Janson C, Braido F, et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532.
   Web of Science ®Google Scholar
• Peché R, Attar-Zadeh D, Scullion J, et al. Matching the inhaler to the patient in COPD. J Clin Med. 2021;10(23):5683.
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107.
   PubMed Web of Science ®Google Scholar
• Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ludwig-Sengpiel A, Ferguson GT, et al. TRONARTO: a randomized, placebo-controlled study of tiotropium/olodaterol delivered via soft mist inhaler in COPD patients stratified by peak inspiratory flow. Int J Chron Obstruct Pulmon Dis. 2021;16:2455–2465.
   PubMed Web of Science ®Google Scholar
• Hartl S, Breyer M-K, Burghuber OC, et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020;55(5):1901874.
   PubMed Web of Science ®Google Scholar
• Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res. 2017;18(1):88.
   PubMedGoogle Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
   PubMed Web of Science ®Google Scholar
• Hinds DR, DiSantostefano RL, Le HV, et al. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016;6(6):e010099.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756.
   PubMed Web of Science ®Google Scholar
• Snoeck-Stroband JB, Lapperre TS, Gosman MM, et al. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J. 2008;31(1):70–77.
   PubMed Web of Science ®Google Scholar
• Singh D, Watz H, Beeh KM, et al. COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition. Eur Respir J. 2020;56(2):2000237.
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (Columbus): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368.
   PubMed Web of Science ®Google Scholar
• Cui Y, Luo L, Li C, et al. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3813.
   PubMed Web of Science ®Google Scholar
• O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol. 2016;196(12):4839–4847.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Zucchelli A, Bianchini E, et al. Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respir.Med. 2019;154:12–17.
   PubMed Web of Science ®Google Scholar
• Axson EL, Ragutheeswaran K, Sundaram V, et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir.Res. 2020;21(1):54.
   PubMed Web of Science ®Google Scholar
• Pirina P, Martinetti M, Spada C, et al. Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting. Respir Med. 2017;131:1–5.
   PubMed Web of Science ®Google Scholar
• Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE study group. Respir Med. 1999;93(3):161–166.
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556.
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15(1):77.
   PubMedGoogle Scholar
• Calverley PMA, Tetzlaff K, Vogelmeier C, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(9):1219–1221.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cardaci V, Cazzola M, et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(4):533–541.
   PubMed Web of Science ®Google Scholar
• Ye Q, He X-O, D’Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther. 2017;3(1):1–18.
   Google Scholar
• World Health Organization. Tuberculosis in the WHO European region. 2019. Available at: https://www.euro.who.int/__data/assets/pdf_file/0008/397484/Factsheet_WHO_WTBD_2019.pdf (Last accessed 2021 Apr 1).
   Google Scholar
• Castellana G, Castellana M, Castellana C, et al. Inhaled corticosteroids and risk of tuberculosis in patients with obstructive lung diseases: a systematic review and meta-analysis of non-randomized studies. Int J Chron Obstruct Pulmon Dis. 2019;14:2219–2227.
   PubMed Web of Science ®Google Scholar
• Andréjak C, Nielsen R, Vø T, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256–262.
   PubMed Web of Science ®Google Scholar
• Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration. 2013;86(1):76–85.
   PubMed Web of Science ®Google Scholar
• Park HJ, Byun MK, Kim HJ, et al. History of pulmonary tuberculosis affects the severity and clinical outcomes of COPD. Respirology. 2018;23(1):100–106.
   PubMed Web of Science ®Google Scholar
• Yakar HI, Gunen H, Pehlivan E, et al. The role of tuberculosis in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:323.
   PubMed Web of Science ®Google Scholar
• Jin J, Li S, Yu W, et al. Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. Int J Chron Obstruct Pulmon Dis. 2018;13:375.
   PubMed Web of Science ®Google Scholar
• Lee C-M, Heo J, Han -S-S, et al. Inhaled corticosteroid-related tuberculosis in the real world among patients with asthma and COPD: a 10-year nationwide population-based study. J Allergy Clin Immunol. 2019;7(4):1197–1206. e1193.
   Web of Science ®Google Scholar
• Kim J-H, Park J-S, Kim K-H, et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143(4):1018–1024.
   PubMed Web of Science ®Google Scholar
• Shu -C-C, Wu H-D, Yu M-C, et al. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore). 2010;89(1):53–61.
   PubMed Web of Science ®Google Scholar
• Huang T-M, Kuo K-C, Wang Y-H, et al. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids. BMC Infect Dis. 2020;20(1):1–8.
   Web of Science ®Google Scholar
• Kim C-J, Yoon H-K, Park M-J, et al. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study. Int J Chron Obstruct Pulmon Dis. 2017;12:1589.
   PubMed Web of Science ®Google Scholar
• Yum H-K, Park I-N. Effect of inhaled tiotropium on spirometric parameters in patients with tuberculous destroyed lung. Tuberc Respir Dis. 2014;77:167–171.
   PubMedGoogle Scholar
• Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019;14:1267–1280.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294.
   PubMed Web of Science ®Google Scholar
• Perez X, Wisnivesky JP, Lurslurchachai L, et al. Barriers to adherence to COPD guidelines among primary care providers. Respir.Med. 2012;106(3):374–381.
   PubMed Web of Science ®Google Scholar
• Chavez PC, Shokar NK. Diagnosis and management of chronic obstructive pulmonary disease (COPD) in a primary care clinic. COPD. 2009;6(6):446–451.
   PubMedGoogle Scholar
• Bourbeau J, Sebaldt RJ, Day A, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J. 2008;15(1):13–19.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Kerkhof M, Soriano JB, et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir.Res. 2016;17(1):120.
   PubMedGoogle Scholar
• Mullerova H, Lu C, Li H, et al. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540.
   PubMed Web of Science ®Google Scholar
• Park J, Hobbs BD, Crapo JD, et al. Subtyping COPD by using visual and quantitative CT imaging features. Chest. 2020;157(1):47–60.
   PubMed Web of Science ®Google Scholar
• Bodduluri S, Reinhardt JM, Hoffman EA, et al. Recent advances in computed tomography imaging in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2018;15(3):281–289.
   PubMed Web of Science ®Google Scholar
• Poggi C, Mantovani S, Pecoraro Y, et al. Bronchoscopic treatment of emphysema: an update. J Thorac Dis. 2018;10(11):6274.
   PubMed Web of Science ®Google Scholar
• Valipour A, Fernandez-Bussy S, Ing AJ, et al. Bronchial rheoplasty for treatment of chronic bronchitis. Twelve-month results from a multicenter clinical trial. Am J Respir Crit Care Med. 2020;202(5):681–689.
   PubMed Web of Science ®Google Scholar
• Slebos D-J, Shah PL, Herth FJ, et al. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. Am J Respir Crit Care Med. 2019;200(12):1477–1486.
   PubMed Web of Science ®Google Scholar